TuHURA Biosciences received FDA clearance to start a Phase 1b trial for TBS-2025, a VISTA-inhibiting antibody targeting relapsed/refractory mutNPM1 Acute Myeloid Leukemia (AML) patients who failed menin inhibitor therapy. This trial will assess safety and efficacy at different doses, addressing a critical unmet need as these patients currently have no approved treatments. Positive results could lead to trial expansion and accelerated approval discussions with the FDA. TuHURA aims to develop novel immunotherapies to overcome resistance in cancer treatment, with TBS-2025 showing promising preclinical survival benefits.
The euro stablecoin market has surged from about €50 million in early 2024 to $835 million by mid-2026, with Ethereum, Solana, and Base dominating 91.5% of the market share. Ethereum leads with nearly 70%, followed by Solana at 14.8%, and Base at 6.9...
Bitget is accelerating its growth beyond cryptocurrency by implementing its Universal Exchange (UEX) strategy, which includes new products like stock perpetual contracts, U.S. stock options, and Hong Kong stock Quanto contracts. Non-crypto assets now...
Chainlink (LINK) is approaching the critical $12 resistance level with a sharp rise in trading volume following recent market volatility. After climbing from $8 to over $13.50 in August-September, LINK corrected to around $11 but maintained a bullish...
Ethereum is approaching a key technical breakout above $2,474, potentially targeting $3,000, supported by strong on-chain activity including large withdrawals to cold storage. This momentum is also impacting Shiba Inu, which shows mixed liquidity flo...
XRP is maintaining its key support level around $1.30 following a strong rally in August, indicating the recent price correction has not turned bearish. The cryptocurrency is trading near $1.38, with buyers defending the $1.30-$1.35 zone and preventi...
